But the ACIP panel voted against recommending a booster dose for people whose jobs or situations put them at high risk of vaccine breakthrough infection.In a similar scenario, the FDA on Wednesday granted Pfizer extended Emergency Use Authorization for boosters for people 65 and older and those at higher risk of severe disease and death, as well as frontline workers at higher risk of breakthrough infections — even though last week, the agency’s safety panel had rejected, in a 16 – 2 vote, Pfizer’s application for boosters for the general population.In opposing Pfizer’s application, the FDA’s Vaccines and Related Biological Products Advisory Committee cited a lack of long-term data and said the vaccine’s risks did not outweigh the benefits for the broader population.
